摘要
目的探讨依达拉奉联合丁苯酞治疗急性脑梗死的疗效及对患者神经功能的影响。方法选择2018年3月至2020年5月汕头市潮南区人民医院收治的89例急性脑梗死患者为研究对象,按照随机数表法分为联合组(n=45)和单一组(n=44)。联合组患者接受依达拉奉联合丁苯酞治疗,单一组患者仅接受依达拉奉治疗,均连续治疗2周。比较两组患者治疗后的症状改善时间、神经功能缺损评分、日常生活能力评分;比较患者治疗前后的血清高敏C反应蛋白(hs-CRP)、内皮素-1、血管内皮细胞生长因子(VEGF)水平,以及治疗后的优良率及不良反应发生率。结果治疗后,联合组患者的症状改善时间为(4.96±0.55)d,明显短于单一组的(6.35±1.45)d,神经功能缺损评分为(5.56±2.26)分,明显低于单一组的(7.39±3.01)分,日常生活能力评分为(68.39±4.62)分,明显高于单一组的(62.01±5.33)分,差异均具有统计学意义(P<0.05);治疗后,联合组患者的血清hs-CRP、内皮素-1水平分别为(2.99±0.57)mg/L、(55.47±9.38)ng/L,明显低于单一组的(5.01±0.69)mg/L和(76.33±9.96)ng/L,VEGF水平为(819.36±155.38)ng/L,明显高于单一组的(712.05±150.39)ng/L,差异均有统计学意义(P<0.05);联合组患者的治疗优良率为95.56%,明显高于单一组的79.55%,差异有统计学意义(P<0.05);两组患者的不良反应发生率比较差异无统计学意义(P>0.05)。结论急性脑梗死依达拉奉联合丁苯酞治疗急性脑梗死能显著改善及恢复患者的神经功能,缓解患者的临床症状,改善各项血清指标,提高治疗效果。
Objective To investigate the efficacy of edaravone combined with butylphthalide in the treatment of acute cerebral infarction and its influence on patients’neurological function.Methods A total of 89 patients with acute cerebral infarction treated in the Shantou Chaonan District People’s Hospital from March 2018 to May 2020 were selected as the study subjects.The patients were divided into two groups:a combined group(n=45)and a single group(n=44).Patients in the combined group were treated with edaravone and butylphthalide,and patients in the single group received only edaravone,both of which were treated continuously for 2 weeks.The time of symptom improvement,neurological deficit score and daily living ability score were compared between the two groups after treatment.The patients’serum levels of high-sensitivity C-reactive protein(hs-CRP),endothelin-1,and vascular endothelial growth factor(VEGF)were compared before and after treatment,as well as the excellent and good rates and the incidence of adverse reactions after treatment.Results After treatment,the symptom improvement time was(4.96±0.55)days in the combined group,which was significantly shorter than(6.35±1.45)days in the single group;the neurological deficit score was(5.56±2.26)points,significantly lower than(7.39±3.01)points in the single group,and the daily living score was(68.39±4.62)points in the combined group,which was significantly higher than(62.01±5.33)points in the single group;all differences were statistically significant(P<0.05).After treatment,the serum levels of hs-CRP and endothelin-1 were respectively(2.99±0.57)mg/L and(55.47±9.38)ng/L in the combined group,which were significantly lower than corresponding(5.01±0.69)mg/L and(76.33±9.96)ng/L in the single group;and the VEGF level was significantly higher in the combined group with(819.36±155.38)ng/L than in the single group with(712.05±150.39)ng/L;all differences were statistically significant(P<0.05).The excellent and good rate was 95.56%in the combined group,which was significantly higher than 79.55%in the single group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the treatment of acute cerebral infarction,edaravone combined with butylphthalide can significantly improve and restore the neurological function of patients with acute cerebral infarction,relieve the clinical symptoms,improve various serum indexes,and improve the therapeutic effect of patients.
作者
黄宝荣
陈伟亮
许尊创
HUANG Bao-rong;CHEN Wei-liang;XU Zun-chuang(Department of Neurology,Shantou Chaonan District People's Hospital,Shantou 515146,Guangdong,CHINA)
出处
《海南医学》
CAS
2021年第12期1537-1540,共4页
Hainan Medical Journal
关键词
急性脑梗死
依达拉奉
丁苯酞
神经功能缺损
疗效
Cerebral infarction
Edaravone
Butylphthalide
Neurological deficit
Therapeutic efficacy
作者简介
通讯作者:黄宝荣,E-mail:huangbaor819@126.com。
